Novartis seeks Japan Stalevo nod as Parkinson's rivals multiply
This article was originally published in Scrip
Responding to rapidly rising competition in the Parkinson's disease sector in Japan, Novartis has filed for the approval in the country of its single pill combination of carbidopa, levodopa and entacapone (licensed from Orion).
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving LegoChem/Pyxix, Biohaven/Sosei Heptares, Kyowa Kirin/Helsinn, Dr. Reddy’s/Glenmark, Eisai/Wren, KoBioLabs/Kolmar Korea, Y-Biologics/Pierre Fabre, Generex/Chinese consortium.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.